News >

Early Administration of Cytarabine May Improve Survival in Pediatric ML-DS

Jason Harris
Published: Wednesday, Sep 13, 2017

mcl
Administering high-dose cytarabine to children with myeloid leukemia of Down syndrome (ML-DS) during the second chemotherapy induction cycle resulted in improved event-free survival (EFS) and overall survival (OS) compared to results observed in previous research studies.

In COG AAMO0431, researchers used the treatment schema from the prior COG A2971 trial with 3 major modifications:
  1. High-dose cytarabine with asparaginase was administered in induction II instead of intensification, thus replacing 1 of 4 cycles of continuous-infusion cytarabine and daunorubicin and reducing the cumulative daunorubicin dose by 25%.
  2. Intensification cycles with moderate-dose cytarabine and etoposide were administered instead of high dose cytarabine.
  3. The number of prophylactic intrathecal doses was reduced from 7 to 2.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x